Enanta Pharmaceuticals Inc
ENTAFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Enanta Pharmaceuticals Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 15 annual periods. The latest annual period ends Sep 30, 2025. The latest insider filing shown is dated Mar 13, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Deep Track Capital, LP | 2026-03-31 | 1,956,867 | $24.7M | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2026-03-31 | 26,593 | $336K | SEC filing |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2026-03-31 | 18,704 | Not shown | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 103,059 | $1.26M | SEC filing |
| NORTHERN TRUST CORP | 2026-03-31 | 240,968 | $3.04M | SEC filing |
| Sio Capital Management, LLC | 2026-03-31 | 40,000 | $505K | SEC filing |
| MARSHALL WACE, LLP | 2026-03-31 | 210,070 | $2.65M | SEC filing |
| MEEDER ASSET MANAGEMENT INC | 2026-03-31 | 2,025 | $25.6K | SEC filing |
| Versant Capital Management, Inc | 2026-03-31 | 1,424 | $18K | SEC filing |
| TUDOR INVESTMENT CORP ET AL | 2026-03-31 | 10,381 | $131K | SEC filing |
| FIFTH THIRD BANCORP | 2026-03-31 | 367 | $4.64K | SEC filing |
| Thrivent Financial for Lutherans | 2026-03-31 | 28,376 | Not shown | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 309,511 | $3.91M | SEC filing |
| DEUTSCHE BANK AG\ | 2026-03-31 | 19,395 | $245K | SEC filing |
| UBS Group AG | 2026-03-31 | 63,804 | $806K | SEC filing |
| CITADEL ADVISORS LLC | 2026-03-31 | 262,533 | $3.32M | SEC filing |
| GROUP ONE TRADING LLC | 2026-03-31 | 91 | $1.15K | SEC filing |
| Advisory Services Network, LLC | 2026-03-31 | 4 | $51 | SEC filing |
| ADAR1 Capital Management, LLC | 2026-03-31 | 51,357 | $649K | SEC filing |
| BANK OF MONTREAL /CAN/ | 2026-03-31 | 33,868 | $428K | SEC filing |
- Each value is checked against Enanta Pharmaceuticals Inc's share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 2 rows: the filed value is about 1,000 times too small for the share count at Enanta Pharmaceuticals Inc's share price.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Enanta Pharmaceuticals Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2023-12-13 · Vance Terry: Larger than 45 of the 48 other insider sales of Common Stock on file. SEC filing
- 2023-03-15 · Or Yat Sun: Larger than 44 of the 48 other insider sales of Common Stock on file. SEC filing
- 2023-03-13 · Luly Jay R.: Larger than 46 of the 48 other insider sales of Common Stock on file. SEC filing
- 2022-04-04 · Adda Nathalie: Larger than 47 of the 48 other insider sales of Common Stock on file. SEC filing
- 2022-04-01 · Adda Nathalie: Larger than all 48 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2025-12-05 | Luu Brendan · Chief Business Officer | Common Stock | S — Open market or private sale | −1,394 | 14.23 | SEC filing |
| 2025-12-05 | Rottinghaus Scott T. · Chief Medical Officer | Common Stock | S — Open market or private sale | −798 | 14.23 | SEC filing |
| 2025-12-05 | Or Yat Sun · Chief Scientific Officer | Common Stock | S — Open market or private sale | −2,390 | 14.23 | SEC filing |
| 2025-12-05 | Kieffer Tara Lynn · Chief Product Strategy Officer | Common Stock | S — Open market or private sale | −2,106 | 14.23 | SEC filing |
| 2025-12-05 | Luly Jay R. · President and CEO | Common Stock | S — Open market or private sale | −4,743 | 14.23 | SEC filing |
| 2025-12-05 | Trout Harry R. III · See Remarks | Common Stock | S — Open market or private sale | −542 | 14.23 | SEC filing |
| 2025-12-05 | Capps Kathleen S. · See Remarks | Common Stock | S — Open market or private sale | −323 | 14.23 | SEC filing |
| 2025-12-02 | Trout Harry R. III · See Remarks | Common Stock | S — Open market or private sale | −380 | 13.96 | SEC filing |
Showing 8 of 11 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-03-11 | Russell Lesley · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-03-11 | Hata Yujiro S · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-03-11 | Vance Terry · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-03-11 | Peterson Kristine · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-03-11 | CARTER BRUCE L A · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-03-11 | FOLETTA MARK G · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +20,000 | SEC filing |
| 2026-02-12 | Kieffer Tara Lynn · Chief Product Strategy Officer | Common Stock | A — Grant, award, or other acquisition | +4,987 | SEC filing |
| 2026-02-12 | Rottinghaus Scott T. · Chief Medical Officer | Common Stock | A — Grant, award, or other acquisition | +1,650 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.